Summary: In a randomised trial, weekly topical application of Wharton’s jelly mesenchymal stem cell-derived exosomes alongside standard care markedly accelerated healing of diabetic foot ulcers compared with standard care alone, with good tolerability.
PICO Summary
| Element | Detail |
|---|---|
| Population | 110 patients with persistent diabetic foot ulcers; randomised controlled clinical trial, Egypt. |
| Intervention | Weekly topical Wharton’s jelly MSC-derived exosomes plus standard of care for 4 weeks. |
| Comparison | Standard of care alone, and standard of care plus the exosome vehicle (CMC) as placebo. |
| Outcome | Overall, 53 patients (62%) fully recovered, with a significantly higher proportion in the exosome group than controls. Mean time to full recovery was 6 weeks (range 4–8) in the treated group versus 20 weeks (range 12–28) in controls. Treatment was well tolerated. |
WJ-MSC Exosomes for Diabetic Foot Ulcers
RCT · diabetic foot ulcers · 4-week course
Weekly topical WJ-MSC exosomes plus standard care healed diabetic foot ulcers in a mean of 6 weeks versus 20 weeks with standard care alone, and were well tolerated. The therapy remains investigational.
Expert Commentary
This is an exciting early-phase trial of genuinely novel technology, and the effect sizes are large, but the appropriate posture is interested caution rather than adoption. The concept is attractive and well-reasoned: rather than transplanting living cells, with their attendant survival, engraftment, and tumorigenicity concerns, this delivers the cell-free exosome cargo of growth factors, anti-inflammatory signals, and pro-angiogenic microRNAs, which addresses several diabetic-wound pathologies at once and offers practical advantages in standardisation, storage, and immunogenicity. The reported acceleration, full recovery in a mean of six weeks versus twenty, is striking and the inclusion of a vehicle-placebo arm strengthens the design. My reservations are those inherent to first-in-area work: a single-centre trial of 110 patients, a four-week treatment course, no long-term durability or recurrence data, and the well-known challenge of standardising exosome potency and quality between batches. Can I use this with my patients? Not yet, and patients should be told plainly that this is investigational and not clinically available. It does not change current practice, where offloading, debridement, infection control, perfusion, and glycaemic management remain foundational, but it is a promising signal worth following as larger confirmatory trials and regulatory pathways develop.
References
Kishta MS, Hafez AM, Hydara T, et al. The transforming role of Wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Res Ther. 2025;16(1):559. doi:10.1186/s13287-025-04690-y